Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3262-3267

  Hoenigl, Martin ^a   Duettmann, Wiebke ^a   Raggam, Reinhard B ^b   Seeber, Katharina ^a   Troppan, Katharina ^a   Fruhwald, Sonja ^a   Prueller, Florian ^b   Wagner, Jasmin ^a   Valentin, Thomas ^a   Zollner Schwetz, Ines ^a   Wölfler, Albert ^a   Krause, Robert ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PROTON PUMP INHIBITOR; RIFAMPICIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BODY MASS INDEX; COHORT STUDIES; DRUG MONITORING; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84879005247     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00251-13     Document Type: Article

References (31)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
2. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
3. Hoenigl M, Salzer HJ, Raggam RB, Valentin T, Rohn A, Woelfler A, Seeber K, Linkesch W, Krause R. 2012. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med. Mycol. 50:266-269.
4. Hoenigl M, Koidl C, Duettmann W, Seeber K, Wagner J, Buzina W, Wolfler A, Raggam RB, Thornton CR, Krause R. 2012. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J. Infect. 65:588-591.
5. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. 2003. Voriconazole. Clin. Ther. 25:1321-1381.
6. Kim SH, Yim DS, Choi SM, Kwon JC, Han S, Lee DG, Park C, Kwon EY, Park SH, Choi JH, Yoo JH. 2011. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int. J. Infect. Dis. 15:e753-8. doi:10.1016/j.ijid.2011.06.004.
7. Hyland R, Jones BC, Smith DA. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547. (Pubitemid 36444162)
8. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:4793-4799.
9. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O. 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokineticsbased analysis of adult patients with invasive fungal infections. Clin. Infect. Dis. 55:381-390.
10. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
11. Mitsani D, Nguyen MH, Shields RK, Toyoda Y, Kwak EJ, Silveira FP, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Clancy CJ. 2012. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob. Agents Chemother. 56:2371-2377.
12. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. 2012. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin. Infect. Dis. 55: 1080-1087.
13. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
14. Chen J, Chan C, Colantonio D, Seto W. 2012. Therapeutic drug monitoring of voriconazole in children. Ther. Drug Monit. 34:77-84.
15. Hoenigl M, Raggam RB, Salzer HJ, Valentin T, Valentin A, Zollner-Schwetz I, Strohmeier AT, Seeber K, Wolfler A, Sill H, Krause R. 2012. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int. J. Antimicrob. Agents 39: 510-513.
16. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
17. Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A, Seeber K, Valentin A, Strohmeier AT, Zollner-Schwetz I, Raggam RB, Urban C, Lass-Florl C, Linkesch W, Krause R. 2012. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J. Antimicrob. Chemother. 67:2029-2033.
18. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788.
19. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
20. Miyakis S, van Hal SJ, Ray J, Marriott D. 2010. Voriconazole concentrations and outcome of invasive fungal infections. Clin. Microbiol. Infect. 16:927-933.
21. Gomez-Lopez A, Cendejas-Bueno E, Cuesta I, Garcia Rodriguez J, Rodriguez-Tudela JL, Gutierrez-Altes A, Cuenca-Estrella M. 2012. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med. Mycol. 50:439-445.
22. Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. 2012. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob. Agents Chemother. 56: 6001-6002.
23. Racil Z, Winterova J, Kouba M, Zak P, Malaskova L, Buresova L, Toskova M, Lengerova M, Kocmanova I, Weinbergerova B, Timilsina S, Rolencova M, Cetkovsky P, Mayer J. 2012. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 55:483-492.
24. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1):56-61. (Pubitemid 37491735)
25. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. 2010. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C1917. Br. J. Clin. Pharmacol. 69:222-230.
26. Lee YJ, Lee SO, Choi SH, Kim YS, Woo JH, Chun S, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH. 2013. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies. Med. Mycol. 51:324-330.
27. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. 2009. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob. Agents Chemother. 53:1793-1796.
28. Hope WW. 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 56:526-531.
29. Koselke E, Kraft S, Smith J, Nagel J. 2012. Evaluation of the effect of obesity on voriconazole serum concentrations. J. Antimicrob. Chemother. 67:2957-2962.
30. Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, Czock D. 2011. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther. Drug Monit. 33:86-93.
31. Shimizu T, Ochiai H, Asell F, Yokono Y, Kikuchi Y, Nitta M, Hama Y, Yamaguchi S, Hashimoto M, Taki K, Nakata K, Aida Y, Ohashi A, Ozawa N. 2003. Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes. Drug Metab. Pharmacokinet. 18:71-78.